Description

McKesson’s $15 Billion GLP-1 Engine — Can The Momentum Keep Building?

McKesson Corporation reported solid results for the first quarter of fiscal 2027, highlighted by an 8% increase in revenues to $105.4 billion and a 20% rise in adjusted earnings per diluted share to $9.93, both surpassing company expectations. These gains were supported by broad-based growth across core segments, with three reporting segments—North American Pharmaceuticals, Oncology and Multispecialty, and Prescription Technology Solutions—delivering double-digit operating profit increases. North American Pharmaceuticals posted a 5% revenue growth driven by increased prescription volumes, particularly in specialty products such as GLP-1 medications, which represented $15 billion in quarterly revenues, up 24% from the prior year. Operating profit in this segment grew by 19%, aided by specialty distribution strength and the timing of new product launches.